This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
This guideline includes recommendations on:
- principles of care
- physiotherapy and occupational therapy
- oral drugs
- botulinum toxin type A
- intrathecal baclofen
- orthopaedic surgery and selective dorsal rhizotomy
Who is it for?
- Healthcare professionals
- Children and young people with spasticity, and their families and carers
Is this guideline up to date?
In November 2016, recommendation 1.1.8 was amended to update information on the World Health Organization’s International Classification of Functioning, Disability and Health (ICF) and the domains it covers.
Next review: 2018
Guideline development process
This guideline was previously called spasticity in children and young people with non-progressive brain disorders: management of spasticity and co-existing motor disorders and their early musculoskeletal complications.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.